Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Oncology Therapeutics, Inc. - Common Stock (NQ:BBOT)

12.33 +0.13 (+1.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 87,888
Open 12.25
Bid (Size) 10.70 (300)
Ask (Size) 13.50 (100)
Prev. Close 12.20
Today's Range 12.11 - 12.44
52wk Range 10.26 - 14.87
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire

Performance

YTD
-0.9%
-0.9%
1 Month
-0.2%
-0.2%
3 Month
-0.9%
-0.9%
6 Month
-0.9%
-0.9%
1 Year
-0.9%
-0.9%

More News

Read More
News headline image
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT to Participate in Upcoming December Investor Healthcare Conferences
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT to Participate in the Jefferies Global Healthcare Conference in London
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire

Frequently Asked Questions

Is BridgeBio Oncology Therapeutics, Inc. - Common Stock publicly traded?
Yes, BridgeBio Oncology Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does BridgeBio Oncology Therapeutics, Inc. - Common Stock trade on?
BridgeBio Oncology Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BridgeBio Oncology Therapeutics, Inc. - Common Stock?
The ticker symbol for BridgeBio Oncology Therapeutics, Inc. - Common Stock is BBOT on the Nasdaq Stock Market
What is the current price of BridgeBio Oncology Therapeutics, Inc. - Common Stock?
The current price of BridgeBio Oncology Therapeutics, Inc. - Common Stock is 12.33
When was BridgeBio Oncology Therapeutics, Inc. - Common Stock last traded?
The last trade of BridgeBio Oncology Therapeutics, Inc. - Common Stock was at 12/26/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.